0001209191-20-041566.txt : 20200707 0001209191-20-041566.hdr.sgml : 20200707 20200707192552 ACCESSION NUMBER: 0001209191-20-041566 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200702 FILED AS OF DATE: 20200707 DATE AS OF CHANGE: 20200707 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stein Steven H CENTRAL INDEX KEY: 0001673776 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 201016997 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-02 0 0000879169 INCYTE CORP INCY 0001673776 Stein Steven H 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 0 1 0 0 EVP & Chief Medical Officer Common Stock 2020-07-02 4 A 0 6661 0.00 A 105015 D Common Stock 2020-07-02 4 F 0 1474 106.47 D 103541 D Common Stock 2020-07-06 4 F 0 269 107.79 D 103272 D Common Stock 2020-07-06 4 S 0 2522 106.40 D 100750 D Common Stock 2020-07-06 4 M 0 596 83.83 A 101346 D Common Stock 2020-07-06 4 S 0 596 107.31 D 100750 D Common Stock 2020-07-06 4 M 0 12132 83.83 A 112882 D Common Stock 2020-07-06 4 S 0 12132 107.31 D 100750 D Common Stock 2020-07-06 4 M 0 10437 72.27 A 111187 D Common Stock 2020-07-06 4 S 0 10437 107.31 D 100750 D Common Stock 2020-07-06 4 M 0 10437 68.62 A 111187 D Common Stock 2020-07-06 4 S 0 10437 107.31 D 100750 D Employee Stock Option (right to buy) 106.47 2020-07-02 4 A 0 12743 0.00 A 2030-07-01 Common Stock 12743 12743 D Incentive Stock Option (right to buy) 83.83 2020-07-06 4 M 0 596 0.00 D 2026-07-14 Common Stock 596 0 D Non-Qualified Stock Option (right to buy) 83.83 2020-07-06 4 M 0 12132 0.00 D 2026-07-14 Common Stock 12132 1194 D Non-Qualified Stock Option (right to buy) 72.27 2020-07-06 4 M 0 10437 0.00 D 2029-01-03 Common Stock 10437 12335 D Non-Qualified Stock Option (right to buy) 68.62 2020-07-06 4 M 0 10437 0.00 D 2028-07-01 Common Stock 10437 12334 D Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Steven Stein's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Represents weighted average sale price. Actual sale prices ranged from $105.52 - $107.29. Represents weighted average sale price. Actual sale prices ranged from $105.64 - $108.24. Represents weighted average sale price. Actual sale prices ranged from $105.65 - $108.48 Including the July 2, 2020 Restricted Stock Unit Grant, this includes an aggregate of 96,857 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Beginning July 2, 2020, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. /s/ Michael J. Purvis, Attorney-In-Fact 2020-07-07